Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAC1 | P63000 | 3/20 | 0.75 |
| ▸ | RAC2 | P15153 | 1/20 | 0.75 |
| ▸ | RAC3 | P60763 | 1/20 | 0.75 |
| ▸ | MET | P08581 | 6/20 | 0.40 |
| ▸ | LDHA | P00338 | 4/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | NCF1 | P14598 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4161227 | 0.96 | RAC1 (0.81) | RAC1RAC2RAC3METLDHA | |
| SCHEMBL1461798 | 0.90 | RAC1 (0.73) | RAC1RAC2RAC3METLDHA | |
| SCHEMBL1461760 | 0.87 | RAC1 (0.84) | RAC1RAC2RAC3METLDHA | |
| SCHEMBL4168881 | 0.87 | RAC1 (0.68) | RAC1RAC2RAC3METLDHA | |
| SCHEMBL1461351 | 0.86 | RAC1 (1.00) | RAC1RAC2RAC3METLDHA | |
| SCHEMBL30798860 | 0.86 | RAC1 (1.00) | RAC1RAC2RAC3METLDHA | |
| Hydrochloric Acid SCHEMBL384979 | 0.85 | RAC1 (1.00) | RAC1RAC2RAC3METLDHA | |
| Hydrochloric Acid SCHEMBL29383079 | 0.85 | RAC1 (1.00) | RAC1RAC2RAC3METLDHA | |
| SCHEMBL4161953 | 0.84 | RAC1 (0.68) | RAC1RAC2RAC3METPDK2 | |
| SCHEMBL1462470 | 0.84 | RAC1 (0.65) | RAC1RAC2RAC3METLDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4648894-B2 | — | — | 2011-03-09 | — | — | JP | claimed |
| US-20090093471-A1 | Methods of Treating Nervous Disorders | EXONHIT THERAPEUTICS SA (FR) | 2009-04-09 | — | — | US | claimed |
| EP-1951247-A2 | METHODS OF TREATING NERVOUS DISORDERS | Exhonit Therapeutics SA (FR) | 2008-08-06 | — | — | EP | claimed |
| WO-2007031878-A2 | METHODS OF TREATING NERVOUS DISORDERS | EXONHIT THERAPEUTICS SA (FR) | 2007-03-22 | — | — | WO | claimed |
| US-20070027146-A1 | Methods of treating nervous disorders | EXONHIT THERAPEUTICS SA (FR) | 2007-02-01 | — | — | US | claimed |
| JP-2006519221-A | — | — | 2006-08-24 | — | — | JP | claimed |
| EP-1597253-B1 | COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES, RETINOPATHIES AND ARTHRITIS | EXONHIT THERAPEUTICS SA (FR) | 2006-08-09 | — | — | EP | claimed |
| EP-1597253-A2 | COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES, RETINOPATHIES AND ARTHRITIS | Exonhit Therapeutics S.A. (FR) | 2005-11-23 | — | — | EP | claimed |
| WO-2004076445-A2 | COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES, RETINOPATHIES AND ARTHRITIS | EXONHIT THERAPEUTICS SA (FR) | 2004-09-10 | — | — | WO | claimed |
| US-20090216014-A1 | NOVEL COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES, RETINOPATHIES AND ARTHRITIS | EXONHIT THERAPEUTICS SA (FR) | 2009-08-27 | — | — | US | disclosed |
| US-20090216014-A1 | NOVEL COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES, RETINOPATHIES AND ARTHRITIS | EXONHIT THERAPEUTICS SA (FR) | 2009-08-27 | — | — | US | disclosed |
| US-20090216014-A1 | NOVEL COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES, RETINOPATHIES AND ARTHRITIS | EXONHIT THERAPEUTICS SA (FR) | 2009-08-27 | — | — | US | disclosed |
| US-20090093471-A1 | Methods of Treating Nervous Disorders | EXONHIT THERAPEUTICS SA (FR) | 2009-04-09 | — | — | US | disclosed |
| US-7514432-B2 | Compounds and methods of treating cell proliferative diseases, retinopathies and arthritis | EXONHIT THERAPEUTICS SA (FR) | 2009-04-07 | — | — | US | disclosed |
| WO-2007031878-A2 | METHODS OF TREATING NERVOUS DISORDERS | EXONHIT THERAPEUTICS SA (FR) | 2007-03-22 | — | — | WO | disclosed |
| US-20070027146-A1 | Methods of treating nervous disorders | EXONHIT THERAPEUTICS SA (FR) | 2007-02-01 | — | — | US | disclosed |
| US-20060183749-A1 | Novel compounds and methods of treating cell proliferative diseases, retinopathies and arthritis | EXONHIT THERAPEUTICS SA (FR) | 2006-08-17 | — | — | US | disclosed |
| EP-1597253-B1 | COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES, RETINOPATHIES AND ARTHRITIS | EXONHIT THERAPEUTICS SA (FR) | 2006-08-09 | — | — | EP | disclosed |
| EP-1597253-A2 | COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES, RETINOPATHIES AND ARTHRITIS | Exonhit Therapeutics S.A. (FR) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004076445-A2 | COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES, RETINOPATHIES AND ARTHRITIS | EXONHIT THERAPEUTICS SA (FR) | 2004-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027146-A1 | Methods of treating nervous disorders | RAC1, GAP43, RAC2 | RAC1 1/4885RAC2 3/4885RAC3 7/4885 |
| US-20090216014-A1 | NOVEL COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES, RETINOPATHIES AND ARTHRITIS | RB1, ALDH1A2, CDK4 | RAC1 789/4885RAC2 1544/4885RAC3 1222/4885 |
| US-20090093471-A1 | Methods of Treating Nervous Disorders | RAC1, IAPP, RAC2 | RAC1 1/4885RAC2 3/4885RAC3 4/4885 |
| US-20060183749-A1 | Novel compounds and methods of treating cell proliferative diseases, retinopathies and arthritis | RB1, ALDH1A2, CDK4 | RAC1 789/4885RAC2 1544/4885RAC3 1222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.